Business & Industry News

Business and Industry News Channel

Lilly and CoLucid Pharmaceuticals announce agreement for Lilly to acquire CoLucid

Eli Lilly and CompanyEli Lilly and Company (NYSE: LLY) and CoLucid Pharmaceuticals, Inc. (NASD: CLCD) have announced an agreement for Lilly to acquire CoLucid for $46.50 per share or approximately $960 million. This all-cash transaction will enhance Lilly's existing portfolio in pain management for migraine, while adding a potential near-term launch to its late-stage pipeline.
Read more ...

Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review

Boehringer IngelheimBoehringer Ingelheim announced that BI 695501, its adalimumab biosimilar candidate to Humira®*, has been accepted for regulatory review by the European Medicines Agency (EMA) and the U.S Food and Drug Administration (FDA).
Read more ...

Sanofi Pasteur and MSD end joint vaccines business in Europe

SanofiSanofi and its vaccines global business unit Sanofi Pasteur confirmed the end of their vaccine joint-venture with MSD (known as Merck & Co. Inc., in the United States and Canada), Sanofi Pasteur MSD (SPMSD). Sanofi Pasteur and MSD will separately pursue their own vaccine strategies in Europe, integrating their respective European vaccines business into their operations.
Read more ...

AstraZeneca and Lilly to develop second potentially disease-modifying treatment for Alzheimer's disease

AstraZenecaAstraZeneca and Eli Lilly and Company have announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials as a potential disease-modifying treatment for Alzheimer's disease (AD).
Read more ...

Merck drives business opportunities in the U.S. to foster innovation across all three business sectors

MerckMerck, a leading science and technology company, today announced two collaborations in the metropolitan area of San Francisco, California (USA). The company is now cooperating with Palantir Technologies Inc., Palo Alto, California, and with the Stanford Graduate School of Business (Stanford GSB), Stanford, California.
Read more ...

FDA grants Roche's cancer immunotherapy TECENTRIQ (atezolizumab) Priority Review in additional type of advanced bladder cancer

RocheRoche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC)
Read more ...

Amgen and Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies

AmgenAmgen (NASDAQ:AMGN) and Immatics Biotechnologies GmbH, a leading company in the field of cancer immunotherapy, have announced a research collaboration and exclusive license agreement to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers.
Read more ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]